Amanda Hoelscher, OD
Optometrist · Dallas, TXNPI 1508874520
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,366 of the $17,769 with a category attached, or 80.8%. 24 manufacturers reported payments, led by Lumenis BE Inc at 45.1% of the total. Reporting peaked in 2023 at $8,136 and has fallen 71.6% since, to $2,311 in 2025. Among optometrist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $96.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE Inc$8K
- Rxsight Inc$3K
- Bausch & Lomb Americas Inc.$2K
- Johnson & Johnson Vision Care, Inc.$856
- Johnson & Johnson Surgical Vision, Inc.$779
- AbbVie$705
- plus $3K from 18 others
Across 22 payments — averaging $1202.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$26K
- Rxsight Inc$16
What the payments were for
- Consulting fees$3,36819%
- Speaking & faculty fees$260%
- Food & beverage$14,36681%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE Inc | 2 | $8,018 |
| Rxsight Inc | 6 | $2,754 |
| Bausch & Lomb Americas Inc. | 17 | $1,650 |
| Johnson & Johnson Vision Care, Inc. | 19 | $856 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $779 |
| AbbVie(2 entities) | 34 | $705 |
| Novartis | 16 | $496 |
| Alcon | 17 | $406 |
| Harrow Eye, LLC | 6 | $305 |
| Sun Pharmaceutical Industries Inc. | 11 | $296 |
| Biotissue Holdings Inc. | 4 | $289 |
| Tarsus Pharmaceuticals, Inc. | 6 | $230 |
| Pfizer | 18 | $193 |
| Oyster Point Pharma, Inc. | 3 | $163 |
| Glaukos Corporation | 3 | $152 |
| Alcon Research LLC | 1 | $134 |
| Aerie Pharmaceuticals, Inc. | 4 | $86 |
| Dompe US, Inc. | 1 | $78 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $52 |
| Amgen(2 entities) | 2 | $36 |
| Astellas Pharma US Inc | 1 | $32 |
| Coopervision Inc. | 1 | $21 |
| Thea Pharma Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- optilight$4,500
- M22$3,518
- RXSIGHT CONTACT LENS$2,568
- RXSIGHT INJECTOR CARTRIDGE$2,568
- RXSIGHT INJECTOR HANDPIECE$2,568
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$2,568
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$2,568
- MIEBO$925
- Tecnis IOL$415
- Acuvue$386
- INFUSE$292
- Tecnis Simplicity$265
- XIIDRA$248
- VEVYE$241
- Prokera$153
- AmnioGraft$153
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$131
- TYRVAYA$129
- XDEMVY$128
- MULTI-FOCAL$124
How this compares
$17,769 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 48 | $74,230 |
| RestasisCyclosporine | 39 | $58,349 |
| XdemvyLotilaner | 20 | $37,677 |
| MieboPerfluorohexyloctane/Pf | 27 | $22,503 |
| CombiganBrimonidine Tartrate/Timolol | 26 | $9,024 |
| LumiganBimatoprost | 11 | $5,904 |
| IlevroNepafenac | 11 | $4,014 |
| Latanoprost | 324 | $3,455 |
| Prednisolone Acetate | 122 | $3,361 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $3,020 |
| Alphagan PBrimonidine Tartrate | 11 | $2,776 |
| Brimonidine Tartrate | 68 | $2,118 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 40 | $863 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 53 | $700 |
| Timolol Maleate | 62 | $533 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $1,650 | $96,73475 claims |
| AbbVieRestasis, Combigan, Lumigan, Alphagan P | $705 | $76,05487 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $230 | $37,67720 claims |
| NovartisIlevro | $496 | $4,01411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Dallas
- Laurence ThomasDallas$103K
- Kenneth UzickDallas$61K
- Lilia FloresDallas$22K
- Derek CunninghamAustin$940K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$547K
- Luis RojasMcKinney$309K
- Emile FadelAustin$225K
- Bridgitte LeeHouston$222K
- Phillip BrunsonHouston$214K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.